/
Business and Products Description Radnostix Inc. (the Company , we , us and our ) manufactures a wide range of radioisotope-focused products used in variety of medical and industrial applications. On December 23, 2025, we filed a Certificate of Amendment in the state of Texas for the sole purpose of amending our Certificate of Formation to change our corporate name from International Is…
The business is unprofitable at the operating level (-7.32% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 6.0% YoY. Margins deteriorated 7.4pp alongside, both lines moving the wrong way.
ROIC dropped from 0.06% to -8.34%, capital efficiency is deteriorating. Net debt of $3M represents 40.3x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
$12M
▼ -6.0% YoY
Net Income (TTM)
-$2M
▼ -10690.2% YoY
Op. Margin
-18.03%
▼ -7.4pp YoY
ROIC
-24.55%
▼ -8.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$58K
▲ +204.3% YoY
Op. Cash Flow (TTM)
$553K
▼ -2.9% YoY
Net Debt
$2M
Cash & Equiv.
$1M
5Y CAGR: +6.9%
5Y CAGR: -40.4%
Continue Research